Search Results - "Trivedi, Niti U"

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review by Mitchell, Aaron P, Trivedi, Niti U, Gennarelli, Renee L, Chimonas, Susan, Tabatabai, Sara M, Goldberg, Johanna, Diaz, Jr, Luis A, Korenstein, Deborah

“…Financial payments from the drug industry to U.S. physicians are common. Payments may influence physicians' clinical decision making and drug prescribing. To…”
Get full text

The Prescription Drug User Fee Act: Much More Than User Fees by Mitchell, Aaron P., Trivedi, Niti U., Bach, Peter B.

“…The Prescription Drug User Fee Act (PDUFA) is due for reauthorization in 2022. Beyond creating the user fee program which now generates a majority of the Food…”
Get full text

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study by Mitchell, Aaron P, Dusetzina, Stacie B, Mishra Meza, Akriti, Trivedi, Niti U, Bach, Peter B, Winn, Aaron N

“…To estimate the association between oncologists' receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value…”
Get more information

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs by Mitchell, Aaron P, Mishra Meza, Akriti, Trivedi, Niti U, Bach, Peter B, Gönen, Mithat

“…Drug manufacturers claim that the purpose of financial payments to physicians is to facilitate education about new drugs. This claim suggests 2 testable…”
Get full text

Quality of Treatment Selection for Medicare Beneficiaries With Cancer by Mitchell, Aaron P, Persaud, Sonia, Mishra Meza, Akriti, Fuchs, Hannah E, De, Prabal, Tabatabai, Sara, Chakraborty, Nirjhar, Dey, Pranam, Trivedi, Niti U, Mailankody, Sham, Blinder, Victoria, Green, Angela, Epstein, Andrew S, Daly, Bobby, Roeker, Lindsey, Bach, Peter B, Gönen, Mithat

“…The Medicare part D Low-Income Subsidy (LIS) improves access to oral cancer drugs, but provides no assistance for clinician-administered/part B drugs. This…”
Get full text

Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017 by Rahman, Mohammed W, Trivedi, Niti U, Bach, Peter B, Mitchell, Aaron P

“…Personal payments from the pharmaceutical industry to US physicians are common and are associated with changes in physicians' clinical practice and…”
Get more information

Posttraumatic stress disorder and functional impairment among World Trade Center Health Registry enrollees 14–15 years after the September 11, 2001, terrorist attacks by Trivedi, Niti U., Gargano, Lisa M., Brackbill, Robert M., Jacobson, Melanie H.

“…The September 11, 2001, terrorist attacks on the World Trade Center (WTC) in New York City (9/11) had health‐related consequences, including posttraumatic…”
Get full text

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines by Mitchell, Aaron P., Mishra, Akriti, Dey, Pranam, Curry, Michael A., Trivedi, Niti U., Haddadin, Michael, Rahman, Mohammed W., Winn, Aaron N., Dusetzina, Stacie B., Bach, Peter B.

“…Background Oncologists who author clinical practice guidelines frequently have financial relationships with the pharmaceutical industry. It is unknown whether…”
Get full text

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines by Mitchell, Aaron P., Mishra, Akriti, Dey, Pranam, Curry, Michael A., Trivedi, Niti U., Haddadin, Michael, Rahman, Mohammed W., Winn, Aaron N., Dusetzina, Stacie B., Bach, Peter B.

Get full text

Trends in financial payments from industry to US cancer centers, 2014-2021 by Chakraborty, Nirjhar, Brown, Meredith, Persaud, Sonia, Gallagher, Grace, Trivedi, Niti U, Bach, Peter B, Mitchell, Aaron P

“…Industry payments to US cancer centers are poorly understood. US National Cancer Institute (NCI)-designated comprehensive cancer centers were identified (n =…”
Get full text

The Prescription Drug User Fee Act by Mitchell, Aaron P, Trivedi, Niti U, Bach, Peter B

“…Background:The Prescription Drug User Fee Act (PDUFA) is due for reauthorization in 2022. Beyond creating the user fee program which now generates a majority…”
Get full text

The Prescription Drug User Fee Act: Much More Than User Fees by Mitchell, Aaron P., Trivedi, Niti U., Bach, Peter B.

Get full text

Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301 by Cotton, Lindsey Behlen, Cisar, Chris, Bach, Peter Brian, Sheridan, Carolina, Trivedi, Niti U., Davis, James, Tennefoss, Demetria

“…TPS11189 Background: To optimize the impact of lung cancer screening at the healthcare system level, additional tools are needed to increase the benefits of…”
Get full text

Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs by Mitchell, Aaron P, Meza, Akriti Mishra, Trivedi, Niti U, Bach, Peter B, Gonen, Mithat

Get full text

Pharmaceutical industry payments to physicians for the promotion of cancer drugs by Mitchell, Aaron Philip, Meza, Akriti Mishra, Trivedi, Niti U., Bach, Peter Brian, Gonen, Mithat

“…1580 Background: Personal financial payments from the pharmaceutical industry to oncologists are common and increasing. A prevalent view is that the purpose of…”
Get full text

Financial payments from the pharmaceutical industry to U.S. cancer centers, 2014-2019 by Mitchell, Aaron Philip, Brown, Meredith, Trivedi, Niti U., Bach, Peter Brian

“…1582 Background: Payments from the pharmaceutical industry to US health care providers were made public through Open Payments in 2013. Since then, industry…”
Get full text

Failure rates of mutation-based ctDNA assays in lung cancer treatment monitoring by Phallen, Jillian, Medina, Jamie E., Trivedi, Niti U., Rinaldi, Lorenzo, Velculescu, Victor E., Bach, Peter Brian, Leal, Alessandro

“…e18752 Background: Despite the wide adoption of noninvasive liquid biopsy approaches for cancer genotyping, little is known about the longitudinal performance…”
Get full text

Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services by Mitchell, Aaron Philip, Dusetzina, Stacie B, Mishra Meza, Akriti, Trivedi, Niti U., Bach, Peter Brian, Winn, Aaron N

“…6639 Background: Personal payments from the pharmaceutical industry to US physicians are common and influence physician practice. Prior studies have found that…”
Get full text

INCORPORATING CLINICAL RISK INTO BIOMARKER-BASED ASSESSMENT USED AS PRESCREENING PRIOR TO LOW-DOSE CT LUNG CANCER SCREENING by BACH, PETER B, U TRIVEDI, NITI, YZ ZONG, YUHUA, B SCHARPF, ROBERT, MADDALA, TARA, JAKUBOWSKI, DEBBIE

Get full text

Abstract 1267: Projected impact of liquid biopsy screening strategies with high sensitivity in focused populations and high specificity in broad populations by Bach, Peter B., Trivedi, Niti U., Cotton, Lindsey

“…Abstract Purpose: Two 'liquid biopsy' cancer screening approaches exist: Focused and Broad. The Focused approach targets specific cancers and populations…”
Get full text